Desatrol 5Mg

DESCRIPTION

Desatrol is the brand name of Desloratadine. Desloratadine is a long-acting tricyclic histamine antagonist with selective histamine 1 (H1) receptor antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/ml (7nanomolar), Desloratadine shows significant interaction with the human histamine 1 (H1)-receptor. 

COMPOSITION

Desatrol Tablet: Each film coated tablet contains Desloratadine INN 5 mg. Desatrol Syrup: Each 5 ml syrup contains Desloratadine INN 2.5 mg. 

CONTRAINDICATIONS

Desatrol is contraindicated in patients who are hypersensitive to this medication or to any of its ingredients, or to loratadine. 

SIDE EFFECTS

Common or very common: Asthenia, dry mouth, headache. Rare or very rare: Akathisia, arrhythmias, diarrhea, dizziness, drowsiness, gastrointestinal discomfort, hallucination, hepatic disorders, insomnia, myalgia, nausea, palpitations seizure, vomiting. Frequency not known: Behavior abnormal, photosensitivity reaction, QT interval prolongation. Side Effects, further information: non-sedating antihistamines such as desloratadine cause less sedation and psychomotor impairment than the older antihistamines, but can still occur, sedation is generally minimal. This is because non-sedating antihistamines penetrate the blood brain barrier to a much lesser extent. 

ALLERGY & CROSS-SENSITIVITY

Contra-indicated if history of hypersensitivity to loratadine. 

PREGNANCY

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is evidence of teratogenicity. 

BREAST FEEDING

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding. 

PRECAUTION & WARNING

Desloratadine should be used as directed. Patients should not increase dose or frequency as somnolence may occur. In general dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal. or cardiac function, and of concomitant disease or another drug therapy. 

DRUG INTERACTIONS

Desloratadine 7.5 mg once daily was co-administered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. Although increased plasma concentration of Desloratadine & 3-hydroxydesloratadine were observed, there were no clinically relevant changes in the safety profile of Desloratadine. 

Navana Pharmaceuticals Ltd